AstraZeneca publish series of B-Raf Kinase inhibitors

AstraZeneca have publsihed a series of amidoheteroaryl B-Raf Kinase inhibitors

AstraZeneca publish series of EphB4 inhibitors

AstraZeneca have published a series of 3,5-bis substituted anilinopyrimidine EphB4 inhibitors

CHK1 inhibitor AZD7762 potentiates antitimor activity in vivo and in vitro

AstraZeneca’s CHK1 inhibitor AZD7762 potentiates antitimor activity in vivo and in vitro when administered in combination with DNA-damaging agents

AstraZeneca publish series of cyclin-dependent kinase inhibitors

AstraZeneca have published a series of Imidazole cyclin-dependent kinase (CDK) inhibitors

AstraZenecas JAK2 inhibitor AZ960 active in vitro

AstraZenecas AZ960 inhibits JAK2 with a Ki of 0.00045 µM in vitro and demostrates apoptic activity in cell based assays

Vandetanib effective in xenograft models of sarcoma

AstraZeneca’s VEGFR2/EGFR inhibitor has shown activity against sarcoma cell lines in xenograft models

AstraZeneca partner with Singapore institutions for HCC

AstraZeneca  is collaborating with the National Cancer Centre Singapore (NCSS) and the National University Hospital (NUH) for the preclinical and clinical development of existing AstraZeneca compounds with potential in inoperable hepatocellular carcinoma (HCC), a common cancer in Asia. The first two compounds identified for screening are MEK inhibitor AZD6244 (ARRY-142886) and Aurora B inhibitor AZD1152.

AstraZeneca initiate Phase I/II trial of mTOR inhibitor AZD8055

AstraZeneca have initiated a Phase I/II trial of mTOR inhibitor AZD8055 in Advance Solid Tumors, Lymphoma and Endometrial Carcinoma

Adding geftinib to FOLFIRI does not improve efficacy in Metastatic colorectal cancer

Phase II data in metastatic colorectal cancer patients has shown that the addition of gefitinib to  FOLFIRI (5-fluorouracil, folinic acid, irinotecan) does not improve outcomes.

AstraZeneca publish series of CSF-1R inhibitors for the treatment of cancer

AstraZeneca have published a series of pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer